Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Catarina Nilsson"'
Autor:
Jane Knöchel, Catarina Nilsson, Björn Carlsson, Linda Wernevik, Alexis Hofherr, Peter Gennemark, Rasmus Jansson‐Löfmark, Rikard Isaksson, Tina Rydén‐Bergsten, Bengt Hamrén, Dinko Rekić
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 12, Pp 1569-1577 (2022)
Abstract Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐hum
Externí odkaz:
https://doaj.org/article/e7f981bc8d2c4134ac07a117e385317e
Autor:
Richard L. Dunbar, Daniel Gaudet, Michael Davidson, Martin Rensfeldt, Hong Yang, Catarina Nilsson, Mats Kvarnström, Jan Oscarsson
Publikováno v:
Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-14 (2020)
Abstract Background Omega-3 fatty acids (OM3-FAs) are recommended with a low-fat diet for severe hypertriglyceridemia (SHTG), to reduce triglycerides and acute pancreatitis (AP) risk. A low-fat diet may reduce pancreatic lipase secretion, which is re
Externí odkaz:
https://doaj.org/article/5b68c5eb56e5404db2b385287af83975
Autor:
Victor Sokolov, Gabriel Helmlinger, Catarina Nilsson, Kirill Zhudenkov, Stanko Skrtic, Bengt Hamrén, Kirill Peskov, Eva Hurt-Camejo, Rasmus Jansson-Löfmark
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 9, Pp 1610-1621 (2019)
Since the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as an attractive target in the treatment of hypercholesterolemia, multiple anti-PCSK9 therapeutic modalities have been pursued in drug development. The objective of this res
Externí odkaz:
https://doaj.org/article/bd39b188292347dca7350be24e8f0568
Autor:
Jane Knöchel, Catarina Nilsson, Björn Carlsson, Linda Wernevik, Alexis Hofherr, Peter Gennemark, Rasmus Jansson‐Löfmark, Rikard Isaksson, Tina Rydén‐Bergsten, Bengt Hamrén, Dinko Rekić
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 11:1569-1577
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::964da33483df2908e46a9f1a1cbf6074
https://doi.org/10.1002/psp4.12866
https://doi.org/10.1002/psp4.12866
Autor:
Dinko Rekić, Ivan Azarov, Jane Knöchel, Victor Sokolov, Catarina Nilsson, Linda Wernevik, David Han, Tina Rydén‐Bergsten, Ahmad Ebrahimi, Corina Dota, Björn Carlsson
Publikováno v:
British Journal of Clinical Pharmacology. 88:4839-4844
AZD8233 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide under development for treatment of hypercholesterolaemia. A prespecified concentration-QT analysis was performed based on data from a single ascending dose s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134aac677ccd322d75dbf14e4da7d520
https://doi.org/10.1111/bcp.15425
https://doi.org/10.1111/bcp.15425
Autor:
Catarina Nilsson, Daniel Gaudet, Martin Rensfeldt, Jan Oscarsson, Mats Kvarnström, Richard L. Dunbar, Michael H. Davidson, Hong Yang
Publikováno v:
Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-14 (2020)
Lipids in Health and Disease
Lipids in Health and Disease
Background Omega-3 fatty acids (OM3-FAs) are recommended with a low-fat diet for severe hypertriglyceridemia (SHTG), to reduce triglycerides and acute pancreatitis (AP) risk. A low-fat diet may reduce pancreatic lipase secretion, which is required to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd5c04457baaeed0a94c685b6ec744ec
http://link.springer.com/article/10.1186/s12944-020-01295-7
http://link.springer.com/article/10.1186/s12944-020-01295-7
Autor:
Kirill Zhudenkov, Bengt Hamrén, Rasmus Jansson-Löfmark, Eva Hurt-Camejo, Catarina Nilsson, Gabriel Helmlinger, Stanko Skrtic, Kirill Peskov, Victor Sokolov
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 9, Pp 1610-1621 (2019)
Journal of Lipid Research
Journal of Lipid Research
Since the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as an attractive target in the treatment of hypercholesterolemia, multiple anti-PCSK9 therapeutic modalities have been pursued in drug development. The objective of this res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db5cee2fd06a636b7abc4f01e227b7dc
https://doi.org/10.1194/jlr.m092486
https://doi.org/10.1194/jlr.m092486
Autor:
Catarina Nilsson, Rosanne M. Crooke, Nigel Davies, Birgitta Rosengren, Brett P. Monia, Eva Hurt-Camejo, Cristina S. J. Rocha, Tina Rydén-Bergsten, Stan Riney, Daniel Lindén, Rosie Z. Yu, Yanfeng Wang, Peter Gennemark, Anna Tivesten, Dorota Kakol-Palm, Ulf Andersson, Lloyd G. Tillman, Marie Elebring, Björn Carlsson, Mikko Hölttä, Jane Knöchel, Linda Wernevik, Rasmus Jansson-Löfmark, Niclas Clemmensen, Rikard Isaksson, Katrin Walter, Richard S. Geary, Dinko Rekić
Publikováno v:
Science Translational Medicine. 13
Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol and are used for treatment of dyslipidemia. Current PCSK9 inhibitors are administered via subcutaneous injection. We present a highly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197948bccc867454748627a58e0b6234
https://doi.org/10.1126/scitranslmed.abe9117
https://doi.org/10.1126/scitranslmed.abe9117
Autor:
Sanjay Bhanot, Jane Knöchel, Brett P. Monia, Catarina Nilsson, Rosanne M. Crooke, Cecilia Arfvidsson, Linda Wernevik, David Han, Alexis Hofherr, Scott P. Henry, Richard S. Geary, Eva Hurt-Camejo, Dinko Rekić, Sotirios Tsimikas, Rikard Isaksson, Björn Carlsson, Kristina Ryden-Bergsten
Publikováno v:
Circulation. 142
Background: AZD8233 is a chemically modified 16-mer antisense oligonucleotide linked to N-acetyl galactosamine (GalNAc) for efficient targeting of PCSK9 mRNA in hepatocytes to prevent the synthesis of PCSK9. We are reporting preliminary data from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::428d9ed2662b3ca16a377d8df86fdef3
https://doi.org/10.1161/circ.142.suppl_3.13913
https://doi.org/10.1161/circ.142.suppl_3.13913
Autor:
Yanfeng Wang, Anna Tivesten, Niclas Clemmensen, Dinko Rekić, Mikko Hölttä, Marie Elebring, Lloyd G. Tillman, Catarina Nilsson, Björn Carlsson, stanley riney, Rosie Z. Yu, Kristina Ryden-Bergsten, Brett P. Monia, Rosanne M. Crooke, Daniel Lindén, Jane Knoechel, Katrin Walter, Eva Hurt-Camejo, Rasmus Jansson-Löfmark, Cristina S. J. Rocha, Peter Gennemark, Ulf Andersson, Nigel Davies
Publikováno v:
Circulation. 142
Current PCSK9 inhibitors are administered via subcutaneous (SC) injection. Here, we present a highly potent, chemically modified PCSK9 antisense oligonucleotide (ASO) with potential for oral delivery. Past attempts at oral delivery using earlier ASO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9933060a0f89627c4a1483b9e72cb980
https://doi.org/10.1161/circ.142.suppl_3.13307
https://doi.org/10.1161/circ.142.suppl_3.13307